TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05430282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only vestibular rehabilitation
Description: Vestibular adaptation exercises, static and dynamic balance exercises, proprioceptive and conditioning exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical exercises in addition to vestibular rehabilitation
Description: Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical exercises in addition to vestibular rehabilitation
Description: Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
Study: NCT06264440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm.
Study: NCT05573373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parimparib
Description: The dosage and protocol of the drug were carried out according to the description.
Study: NCT06264440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Administered as specified in the treatment arm.
Study: NCT05499741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forehead Temperature-Regulating Therapy
Description: A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
Study: NCT05573373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parimparib
Description: The dosage and protocol of the drug were carried out according to the description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: The dosage and protocol of the drug were carried out according to the description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Therapy Agent
Description: The dosage and protocol of the drug were carried out according to the description.
Study: NCT05409014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT
Description: The phase 1 of the protocol was awareness-raising, the athlete receives guidance from a physical therapist and learns the location of the PFM and the ability to contract them in isolation. The phase 2 is stabilization, consisting of 15 stabilization exercises, which are performed through pelvic floor contractions for 10 seconds and with the same relaxation time, repeating each group 10 times. The phase 3 is strength, the same exercises as the second phase are performed using 2 kg weights at the end of each leg and/or arm. There are eight groups of exercises and with changes in the time of slow contraction and relaxation. The phase 4 is power, in power exercises the training loads are increased and the sequence of movements is also increased. The phase 5 is to complement the power, this phase was the continuation of the previous one in the sense of potentiation of the results where ballistic movements, speed and impact fundamentally predominate.
Study: NCT05257525

Intervention type: OTHER
Group type: OTHER
Intervention: Esophageal manometry catheter at various PEEP levels and tidal volumes
Description: Participants will undergo placement of an esophageal manometry catheter before planned sternal closure. This catheter will be used to measure esophageal pressure which is a surrogate for pleural (intrathoracic) pressure. Esophageal pressure will then be used to estimate changes in respiratory system mechanics and hemodynamics following sternal closure and across different levels of positive end-expiratory pressure (PEEP) and tidal volumes.

Intervention type: OTHER
Group type: OTHER
Intervention: Esophageal manometry catheter at various PEEP levels and tidal volumes
Description: Participants will undergo placement of an esophageal manometry catheter before planned sternal closure. This catheter will be used to measure esophageal pressure which is a surrogate for pleural (intrathoracic) pressure. Esophageal pressure will then be used to estimate changes in respiratory system mechanics and hemodynamics following sternal closure and across different levels of positive end-expiratory pressure (PEEP) and tidal volumes.
Study: NCT04223661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide Pill
Description: Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide Pill
Description: Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
Study: NCT06244745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of letrozole
Description: Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.
Study: NCT05348642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pasteurized A. muciniphila
Description: pasteurized A. muciniphila - oral daily dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo = identical to verum regarding the form, size, taste, color and intake
Study: NCT04825509

Intervention type: DEVICE
Intervention: Ultrasound
Description: Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line.

Intervention type: DEVICE
Intervention: Ultrasound
Description: Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line.
Study: NCT05875766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathy
Description: 4 sessions of osteopathy after DIDT surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy after DIDT surgery (reference treatment)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy after DIDT surgery (reference treatment)
Study: NCT06043999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical total mesorectal excision
Description: Standard TME surgery was performed 3-4 weeks after local resection. The operation is roughly divided into the following steps:After abdominal exploration, gradually ligation and from the inferior mesenteric vessels, pay attention to protect the left ureter, reproductive blood vessels and upper abdominal nerve; The descending colon was fully mobilized and the splenic flexure was mobilized if necessary. Follow the principle of TME, perform sharp resection of the total mesorectum, and pay attention to the protection of the prostate, vagina, pelvic nerve, etc.For can be removed through double stapling technique in low former (LAR) need not inline sphincter resection (excluding cases), to must be inline sphincter resection can be turned to the anus operation (ditto), consistent way can choose according to the intraoperative situation drag anastomosis or manual suture or stapling anastomosis. Prophylactic loop colostomy of transverse colon or ileostomy is recommended.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salavge Adjuvant Chemoradiotherapy
Description: Concurrent adjuvant chemotherapy:5-Fu or 5-Fu analogues based chemotherapy regimens were selected. CapeOx or capecitabine monotherapy or FOLFOX is recommended, and no more than 3 months.Adjuvant radiotherapy protocol:long-course radiotherapy protocol.a. Target definition: areas at high risk for recurrence of the primary tumor and regional lymphatic drainage.b. Radiotherapy technology: conventional radiotherapy, three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy, etc.c. Radiation dose:DT of 45Gy,1.8Gy per fraction in 25 fractions, was recommended for the high-risk recurrence area of the primary tumor and the regional lymphatic drainage area.
Study: NCT06526767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsules twice a week
Description: Subjects in control group took Vibrabot capsules twice a week, one pill/time (on Monday and Thursday), for six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsules three times a week
Description: Subjects in trial group 1 took Vibrabot capsules three times a week, one pill/time (Monday, Wednesday, and Friday) for six consecutive weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsules five times a week
Description: Subjects in trial group 2 took Vibrabot capsules five times a week, one pill/time (Monday, Tuesday, Wednesday, Friday, and Saturday), for six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsules loading dose
Description: Subjects in trial group 3 took Vibrabot capsules one pill/time, five times a week (Monday, Tuesday, Wednesday, Friday, and Saturday) during the first two weeks, three times a week (Monday, Wednesday, and Friday) during the middle two weeks, and two times a week (Monday and Thursday) during the last two weeks.
Study: NCT06529523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).
Study: NCT05483439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Description: Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Study: NCT06030297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser fiber type Selective Stimulator
Description: -Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fib
Study: NCT05772793

Intervention type: DEVICE
Intervention: Telerehabilitation
Description: The home visual telerehabilitation path using the EyeFitness software consisted of performing one visual training session per day, 5 days a week (from Monday to Friday) for a total of 6 weeks.
Study: NCT06467045

Intervention type: OTHER
Intervention: Pediatric patients who received sedation for magnetic resonance imaging
Description: Pediatric patients who underwent MRI under sedation will be prospectively observed. All non-intubated patients under the age of 16 will be included in the study. The demographic data, comorbidities, and medications of the patients, the procedures performed, the anesthetic drugs used, the expertise duration of the anesthesiologist, and the adverse effects encountered will be recorded.
Study: NCT06388876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Members of the exercise group received an exercise intervention twice a week for six weeks accompanied by a physiotherapist.
Study: NCT05123365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Given PO
Study: NCT05483439

Intervention type: DRUG
Group type: OTHER
Intervention: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Description: Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Study: NCT06030297

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medoc Quantitative Sensory Testing
Description: Quantitative sensory testing (QST) is a method through which sensory nerve function is quantitatively measured, based on responses of the subject. The peripheral sensory nervous system responds to specific stimuli of specific modality and intensity in a specific manner, which is well-known through many decades of research into human sensation. Thermal QST provides information about the function of small diameter unmyelinated (C fibers) and thinly myelinated (A-delta fibers) nerve fibers for which no nerve conduction test, or other objective tests exist.~Small fiber nerve damage can manifest itself in thermal hypoesthesia (raised perception thresholds) or hyperalgesia (lowered pain thresholds).

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Medoc Quantitative Sensory Testing
Description: Quantitative sensory testing (QST) is a method through which sensory nerve function is quantitatively measured, based on responses of the subject. The peripheral sensory nervous system responds to specific stimuli of specific modality and intensity in a specific manner, which is well-known through many decades of research into human sensation. Thermal QST provides information about the function of small diameter unmyelinated (C fibers) and thinly myelinated (A-delta fibers) nerve fibers for which no nerve conduction test, or other objective tests exist.~Small fiber nerve damage can manifest itself in thermal hypoesthesia (raised perception thresholds) or hyperalgesia (lowered pain thresholds).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Medoc Quantitative Sensory Testing
Description: Quantitative sensory testing (QST) is a method through which sensory nerve function is quantitatively measured, based on responses of the subject. The peripheral sensory nervous system responds to specific stimuli of specific modality and intensity in a specific manner, which is well-known through many decades of research into human sensation. Thermal QST provides information about the function of small diameter unmyelinated (C fibers) and thinly myelinated (A-delta fibers) nerve fibers for which no nerve conduction test, or other objective tests exist.~Small fiber nerve damage can manifest itself in thermal hypoesthesia (raised perception thresholds) or hyperalgesia (lowered pain thresholds).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Topical System
Description: Inactive, non-medicated topical system comprised of an adhesive material containing, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of the system is 10 cm × 14 cm × 0.08 cm.
Study: NCT05000164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch + Lomb Ultra® Multifocal for Astigmatism
Description: Study Lens
Study: NCT04118387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide + supplemental oxygen + PAP therapy
Description: Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem + PAP therapy
Description: The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone + PAP therapy
Description: The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
Study: NCT06388876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle advice
Description: At the beginning of the program, the members of the individuals were given lifestyle recommendations, both verbally and in writing (in the form of a brochure) within the scope of a common training initiative.The individuals groups received both written (brochure) and verbal training within the scope of lifestyle recommendations (the effects of planned and regular exercise, sleep problems, methods of coping with stress, etc.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle advice
Description: At the beginning of the program, the members of the individuals were given lifestyle recommendations, both verbally and in writing (in the form of a brochure) within the scope of a common training initiative.The individuals groups received both written (brochure) and verbal training within the scope of lifestyle recommendations (the effects of planned and regular exercise, sleep problems, methods of coping with stress, etc.).
Study: NCT05413811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil (5 FU) Cream
Description: Intravaginal topical chemotherapy, 5-fluorouracil cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravaginal topical placebo cream
Study: NCT05827809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP-C/A) for children and youth with anxiety disorders and /or depression
Description: A transdiagnostic psychological group treatment, Unified Protocol (UP-C/A), one intervention, is tested for children and youth with anxiety disorders and/or depression seeking help in routine care in two primary care locations. Parents are at the same time offered parent training in a group format coupled with the module the children are working on. Feasibility, acceptability and effect of the intervention will be studied, with child self-report, parent-report and therapist assessment.
Study: NCT06388577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants in the intervention group (n = 36) will be administered the Epilepsy Education Programme based on Pender's Health Promotion Model by the researcher and will be given the education booklet developed by the researcher in line with the literature. The training topics of the intervention programme are: General information about epilepsy, seizure moment management, management of antiepileptic drug treatments, controlling the factors that may trigger seizures, and recommendations to parents about health promoting and protective behaviours. In the training, learning and teaching techniques such as presentation, video demonstration, question and answer sections, lecture and discussion will be applied. The training will last approximately one hour.
Study: NCT04625803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab , apatinib and chemotherapy
Description: Camrelizumab 200 mg, IV infusion on Days 1 each 14-day cycle~Apatinib 250mg oral administration once a day, for two months~mFOLFOX6 oxaliplatin 85 mg/m\^2 IV infusion on Day 1 of each14-day cycle. Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2. The loading dose is then followed by a 46-hour 5-fluorouracil infusion of 2,400 mg/m2 via a pump programmed to provide a constant drug infusion rate.
Study: NCT05971758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimepinostat
Description: The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimepinostat
Description: The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.